|Institutional Source||Beutler Lab|
|Gene Name||vasoactive intestinal peptide receptor 2|
|Synonyms||VPAC2R, VPAC2, VIP receptor subtype 2, Vip2|
|Is this an essential gene?||Probably non essential (E-score: 0.057)|
|Stock #||R6902 (G1)|
|Chromosomal Location||116077726-116146261 bp(+) (GRCm38)|
|Type of Mutation||missense|
|DNA Base Change (assembly)||A to T at 116139199 bp|
|Amino Acid Change||Threonine to Serine at position 310 (T310S)|
|Ref Sequence||ENSEMBL: ENSMUSP00000011315 (fasta)|
|Gene Model||predicted gene model for transcript(s): [ENSMUST00000011315]|
|Predicted Effect||possibly damaging
AA Change: T310S
PolyPhen 2 Score 0.456 (Sensitivity: 0.89; Specificity: 0.90)
AA Change: T310S
|Meta Mutation Damage Score||0.0799|
|Coding Region Coverage||
|Validation Efficiency||98% (50/51)|
FUNCTION: [Summary is not available for the mouse gene. This summary is for the human ortholog.] This gene encodes a receptor for vasoactive intestinal peptide, a small neuropeptide. Vasoactive intestinal peptide is involved in smooth muscle relaxation, exocrine and endocrine secretion, and water and ion flux in lung and intestinal epithelia. Its actions are effected through integral membrane receptors associated with a guanine nucleotide binding protein which activates adenylate cyclase. [provided by RefSeq, Aug 2011]
PHENOTYPE: Homozygotes for a targeted null mutation exhibit enhanced delayed-type hypersensitivity (type IV) and reduced immediate-type hypersensitivity (type I). [provided by MGI curators]
|Allele List at MGI|
|Other mutations in this stock||
|Other mutations in Vipr2||
(F):5'- CACAACTTTATGCAGTAGTACCCTC -3'
(R):5'- AGACTCCAGTGTCAGTGCAC -3'
(F):5'- TATGCAGTAGTACCCTCAATGC -3'
(R):5'- CAGTGCACGTTGAGCCTTAGAG -3'